JRKL-AS1

Across TCGA pan-cancer cohorts, JRKL-AS1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of JRKL-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where JRKL-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types JRKL-AS1 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

KIRC, LUAD, and UCEC are the cancer types where JRKL-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JRKL-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−0.101	.012	3	view →
LUAD	Female	All	+0.093	.003	3	view →
UCEC	All	All	+0.120	.031	2	view →
LUSC	Male	All	+0.058	.017	2	view →
BRCA	Female	II,III,IV	+0.022	.032	2	view →
HNSC	All	IV	+0.046	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

JRKL-AS1–KIRC

Open the KIRC breakdown →